EA200900259A1 - Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением - Google Patents

Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением

Info

Publication number
EA200900259A1
EA200900259A1 EA200900259A EA200900259A EA200900259A1 EA 200900259 A1 EA200900259 A1 EA 200900259A1 EA 200900259 A EA200900259 A EA 200900259A EA 200900259 A EA200900259 A EA 200900259A EA 200900259 A1 EA200900259 A1 EA 200900259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
glukocorticoides
rheumatoid disease
relaxed
delivery
Prior art date
Application number
EA200900259A
Other languages
English (en)
Other versions
EA015304B1 (ru
Inventor
Ахим Шэффлер
Original Assignee
Нитек Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38739340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200900259(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нитек Фарма Аг filed Critical Нитек Фарма Аг
Publication of EA200900259A1 publication Critical patent/EA200900259A1/ru
Publication of EA015304B1 publication Critical patent/EA015304B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к лечению ревматического заболевания и/или остеоартрита введением лекарственной формы глюкокортикоида с отсроченньм высвобождением субъекту, нуждающемуся в этом.
EA200900259A 2006-08-03 2007-08-03 Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением EA015304B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83509306P 2006-08-03 2006-08-03
PCT/EP2007/006894 WO2008015018A1 (en) 2006-08-03 2007-08-03 Delayed-release glucocorticoid treatment of rheumatoid disease

Publications (2)

Publication Number Publication Date
EA200900259A1 true EA200900259A1 (ru) 2009-06-30
EA015304B1 EA015304B1 (ru) 2011-06-30

Family

ID=38739340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900259A EA015304B1 (ru) 2006-08-03 2007-08-03 Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением

Country Status (27)

Country Link
US (5) US20080076743A1 (ru)
EP (1) EP2049123B2 (ru)
JP (1) JP2009545546A (ru)
KR (1) KR101430089B1 (ru)
CN (1) CN101466385B (ru)
AU (1) AU2007280636B2 (ru)
BR (1) BRPI0717052A2 (ru)
CA (1) CA2655682A1 (ru)
DK (1) DK2049123T4 (ru)
EA (1) EA015304B1 (ru)
ES (1) ES2400446T5 (ru)
HK (1) HK1130423A1 (ru)
HR (1) HRP20130148T4 (ru)
IL (1) IL195155A (ru)
MA (1) MA30665B1 (ru)
MX (1) MX2009001248A (ru)
MY (1) MY149863A (ru)
NO (1) NO20090958L (ru)
PL (1) PL2049123T5 (ru)
PT (1) PT2049123E (ru)
RS (1) RS52672B2 (ru)
SG (2) SG10201503411QA (ru)
SI (2) SI2049123T1 (ru)
TN (1) TNSN08385A1 (ru)
UA (1) UA96457C2 (ru)
WO (1) WO2008015018A1 (ru)
ZA (1) ZA200809858B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619869C2 (ru) * 2012-02-13 2017-05-18 Дайэрнал Лимитед Композиция гидрокортизона с контролируемым высвобождением

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
PT2563450T (pt) * 2010-04-28 2017-08-28 Kimberly Clark Co Dispositivo para entrega de medicação para a artrite reumatóide
RU2014117510A (ru) * 2011-10-10 2015-11-20 Медиммьюн Лимитед Лечение ревматоидного артрита
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
BE629982A (ru) 1962-04-06
FR1603314A (en) 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2100858B1 (ru) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
DE2445971A1 (de) 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5519057A (en) 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3930770A1 (de) 1989-09-14 1991-03-28 Wolfgang F Dr Schoener Implantierbare katheter aus medizinisch vertraeglichem elastischen kunststoff
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
ES2056470T3 (es) 1990-07-02 1994-10-01 Boehringer Mannheim Gmbh Proceso para la obtencion de dosis unitarias de liberacion retardada, prensadas en molde, y las dosis unitarias correspondientes.
JP2521848B2 (ja) 1990-07-02 1996-08-07 ベーリンガー マンハイム ゲーエムベーハー 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5310578A (en) 1990-09-17 1994-05-10 Merck Patent Gesellschaft Deposition of cosmetically functional material onto pigments and fillers
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
EP0565560B1 (en) 1991-01-03 1994-09-28 Glaxo Canada Inc. Method for production of solid pharmaceutical preparation
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
DE69222006T2 (de) 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
AU3949093A (en) 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
GB9215908D0 (en) 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
CA2142982A1 (en) 1992-09-30 1994-04-14 Julian Belknap Lo Articles for sustained release of medications
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
TW272942B (ru) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5709880A (en) 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU1751997A (en) 1996-01-30 1997-08-22 Advanced Polymer Systems Inc. Targeted delivery of drugs to the lower gastrointestinal tract
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
CA2305762C (en) 1997-10-09 2006-09-26 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1067910B1 (en) 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
GB9905898D0 (en) 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
WO2001080824A2 (en) 2000-04-19 2001-11-01 Eurand America, Inc. Dual mechanism timed release dosage forms for low dose drugs
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
AU2002252364B2 (en) 2001-03-13 2005-08-25 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EP1392321B1 (en) 2001-03-15 2010-08-18 Soligenix, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
IN191028B (ru) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
WO2003011255A1 (en) 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
CN1596100A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 可食用组合物及含可食用外壳的制剂
DK1443912T3 (da) 2001-10-12 2008-01-21 Elan Pharma Int Ltd Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber
US20080145438A1 (en) 2001-12-20 2008-06-19 Beuford Arlie Bogue Micro- and nano-particulate drugs and methods of making thereof
CA2472188C (en) 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
AU2003208761A1 (en) 2002-02-21 2003-09-09 Amarin Development Ab A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
WO2003075919A1 (fr) 2002-03-14 2003-09-18 Daiichi Suntory Pharma Co.,Ltd. Comprime contenant du chlorhydrate de pilsicainide (voie seche)
AU2003230691A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
WO2004028510A1 (en) 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Delayed release dosage forms
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004043440A1 (en) 2002-11-12 2004-05-27 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
ATE445393T1 (de) 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
PL1631251T3 (pl) * 2003-04-24 2011-12-30 Jagotec Ag Tabletka o opóźnionym uwalnianiu i o określonej geometrii
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
WO2005027843A2 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
KR101363563B1 (ko) * 2004-09-10 2014-02-14 자고텍 아게 활성성분의 부위 및 시간 제어적 위장관 방출 정제
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US20070065359A1 (en) 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
RU2385712C2 (ru) 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
JP2009543797A (ja) 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
US20080014272A1 (en) 2006-07-11 2008-01-17 Phil Skolnick Compositions and Methods for Treatment of Chronic Pain Conditions
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CA2660029A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR101575679B1 (ko) 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US20080166303A1 (en) 2006-09-08 2008-07-10 Dov Tamarkin Colored or colorable foamable composition and foam
WO2008033351A2 (en) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
WO2008059502A2 (en) 2006-11-14 2008-05-22 Yissum Research Development Company Contact lens compositions
WO2008079963A2 (en) 2006-12-22 2008-07-03 Cambrex Charles City, Inc. Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
US20080181932A1 (en) 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20100016322A1 (en) 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
WO2008128191A2 (en) 2007-04-13 2008-10-23 Chemgenex Pharmaceuticals, Inc. Oral cephalotaxine dosage forms
WO2008127794A2 (en) 2007-04-13 2008-10-23 Dow Global Technologies Inc. Granular material for dosage forms
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
KR20100063059A (ko) 2007-08-13 2010-06-10 파나세아 바이오테크 리미티드 마이폴틱 장용정을 함유하는 서방출형 조성물 및 이의 조제방법
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
US20110091566A1 (en) 2007-09-25 2011-04-21 Nirmal Mulye Controlled release pharmaceutical compositions
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
JP2011500553A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
JP2011507860A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
EP2242844A2 (en) 2007-12-21 2010-10-27 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
JP2011507861A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
MX2010009704A (es) 2008-03-05 2010-12-20 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion modifcada que comprenden micofenolato y procesos de estas.
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2010005687A1 (en) 2008-06-12 2010-01-14 University Of Alabama Huntsville Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases or trauma
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
AU2010207740B2 (en) 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619869C2 (ru) * 2012-02-13 2017-05-18 Дайэрнал Лимитед Композиция гидрокортизона с контролируемым высвобождением

Also Published As

Publication number Publication date
PT2049123E (pt) 2013-03-06
TNSN08385A1 (en) 2009-12-29
NO20090958L (no) 2009-04-30
RS52672B2 (sr) 2018-03-30
AU2007280636B2 (en) 2013-07-18
MX2009001248A (es) 2009-02-11
RS52672B (en) 2013-06-28
EP2049123B1 (en) 2012-11-28
CN101466385A (zh) 2009-06-24
SG174026A1 (en) 2011-09-29
PL2049123T5 (pl) 2017-09-29
DK2049123T4 (en) 2016-11-28
SG10201503411QA (en) 2015-06-29
KR20090045149A (ko) 2009-05-07
US20170281648A1 (en) 2017-10-05
AU2007280636A1 (en) 2008-02-07
DK2049123T3 (da) 2013-03-04
US8920838B2 (en) 2014-12-30
KR101430089B1 (ko) 2014-08-13
ES2400446T5 (es) 2017-03-13
IL195155A0 (en) 2009-09-22
BRPI0717052A2 (pt) 2013-10-15
ES2400446T3 (es) 2013-04-09
HK1130423A1 (en) 2009-12-31
HRP20130148T4 (hr) 2016-10-07
EP2049123A1 (en) 2009-04-22
US20150141388A1 (en) 2015-05-21
MA30665B1 (fr) 2009-08-03
US20120070499A1 (en) 2012-03-22
US20140065214A1 (en) 2014-03-06
UA96457C2 (ru) 2011-11-10
US20080076743A1 (en) 2008-03-27
US9504699B2 (en) 2016-11-29
IL195155A (en) 2016-05-31
CA2655682A1 (en) 2008-02-07
PL2049123T3 (pl) 2013-04-30
ZA200809858B (en) 2009-10-28
EA015304B1 (ru) 2011-06-30
WO2008015018A1 (en) 2008-02-07
MY149863A (en) 2013-10-31
SI2049123T1 (sl) 2013-04-30
JP2009545546A (ja) 2009-12-24
SI2049123T2 (sl) 2016-10-28
EP2049123B2 (en) 2016-08-24
HRP20130148T1 (en) 2013-03-31
CN101466385B (zh) 2014-01-08

Similar Documents

Publication Publication Date Title
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CR10347A (es) Anticuerpos contra el peptidob-amiloide
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA200900259A1 (ru) Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
UA109658C2 (xx) Антитіло проти cgrp
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
WO2009037583A3 (en) Compositions and methods for treatment and prevention of osteoarthritis
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
CL2011000678A1 (es) Uso de una composicion combinada de ibuprofeno y paracetamol para preparar un medicamento para el tratamiento de osteoartritis o artritis reumatoidea.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU